Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma 

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.
 

Dr Kumethaker on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease  

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Researchers at Moffitt Cancer Center published an article in Cancer Cell showing that necroptosis-mediated immune suppression occurs through release of IL-1α.

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.  

BTK Inhibitor–Based Combinations Represent the Future of MCL Management

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.  

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC)

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC 

How do you select patients for consolidation durvalumab?

Videos

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC 

The panel discusses reassessing for respectability after certain treatments.

Management of Borderline Resectable NSCLC

The panel discusses management of resectable early-stage non–small cell lung cancer.

Management of Resectable Early Stage NSCLC with Actionable Mutations

The panel discusses the factors that go into selecting patients for adjuvant therapy.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

The panel looks at a second patient case study.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease 

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

The panel discusses treatment considerations for consolidation durvalumab.

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

EP: 1.Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

EP: 2.Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

EP: 3.Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

EP: 4.Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

EP: 5.Management of Borderline Resectable NSCLC

EP: 6.Management of Resectable Early Stage NSCLC with Actionable Mutations

EP: 7.Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

EP: 8.Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

EP: 9.Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

EP: 10.Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Latest Conference Coverage